Numerous genetic and epigenetic alterations are involved in the development and progression of NSCLC, comprising mutations in key genes such as epidermal growth factor receptor (EGFR), ALK tyrosine kinase receptor (ALK), and Kirsten rat sarcoma viral oncogene homolog (KRAS) [4]. This evidence concerns the gene ALK and non-small cell lung carcinoma.